We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00763061
Recruitment Status : Completed
First Posted : September 30, 2008
Results First Posted : January 26, 2010
Last Update Posted : March 2, 2010
Information provided by:

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Condition: Glaucoma
Interventions: Drug: Travoprost 0.004% Ophthalmic Solution (Travatan)
Drug: Timolol 0.5% Ophthalmic Solution (Timoptic)

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
111 patients were enrolled in this study at 4 hospitals

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Eligibility patients were washed out for up to 4 weeks before randomization

Reporting Groups
Travoprost 0.004% Travoprost at 9 AM + Placebo & 9 PM
Timolol 0.5% Timolol in each eye, twice daily at 9 AM & 9 PM

Participant Flow:   Overall Study
    Travoprost 0.004%   Timolol 0.5%
STARTED   54   57 
COMPLETED   49   44 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Travoprost 0.004% Travoprost at 9 AM + Placebo & 9 PM
Timolol 0.5% Timolol in each eye, twice daily at 9 AM & 9 PM
Total Total of all reporting groups

Baseline Measures
   Travoprost 0.004%   Timolol 0.5%   Total 
Overall Participants Analyzed 
[Units: Participants]
 54   57   111 
[Units: Participants]
<=18 years   2   1   3 
Between 18 and 65 years   33   31   64 
>=65 years   19   25   44 
[Units: Participants]
Female   22   26   48 
Male   32   31   63 

  Outcome Measures

1.  Primary:   Mean Intraocular Pressure (IOP) at 9 AM   [ Time Frame: At Week 12 - At the 9 AM time point for the patient's worse eye. ]

2.  Primary:   Week 12 - Mean IOP At 4 PM   [ Time Frame: At the 4 PM time point for the patient's worse eye. ]

3.  Secondary:   Mean IOP Change From Baseline at 9 AM   [ Time Frame: Baseline to Week 12 - at 9 AM ]

4.  Secondary:   Mean IOP Change at 4 PM   [ Time Frame: Baseline to Week 12 - at 4 PM ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Alcon Clinical
Organization: Alcon Research, Ltd.
phone: 888.451.3937; 817.568.6725
e-mail: medinfo@alconlabs.com

Responsible Party: Benny Li, Ph.D., Alcon Research Ltd
ClinicalTrials.gov Identifier: NCT00763061     History of Changes
Other Study ID Numbers: MS-06-02
First Submitted: September 26, 2008
First Posted: September 30, 2008
Results First Submitted: April 28, 2009
Results First Posted: January 26, 2010
Last Update Posted: March 2, 2010